Ciprofibrate
Ciprofibrate[edit]
Ciprofibrate is a fibrate class medication primarily used to treat dyslipidemia, particularly in cases of hyperlipidemia where there is an elevated level of triglycerides and cholesterol in the blood. It is known for its ability to lower low-density lipoprotein (LDL) cholesterol and triglycerides while modestly increasing high-density lipoprotein (HDL) cholesterol.
Mechanism of Action[edit]
Ciprofibrate works by activating the peroxisome proliferator-activated receptor alpha (PPAR_), a type of nuclear receptor that regulates the expression of genes involved in lipid metabolism. Activation of PPAR_ leads to increased oxidation of fatty acids in the liver and muscle, reduced production of triglycerides, and increased clearance of very-low-density lipoprotein (VLDL) particles from the bloodstream.
Clinical Use[edit]
Ciprofibrate is indicated for the treatment of severe hypertriglyceridemia and mixed dyslipidemia, particularly when dietary measures and other non-pharmacological interventions have not been sufficient. It is often used in combination with other lipid-lowering agents such as statins to achieve better control of lipid levels.
Side Effects[edit]
Common side effects of ciprofibrate include gastrointestinal disturbances such as nausea, vomiting, and diarrhea. It may also cause muscle pain and weakness, which can be indicative of myopathy or rhabdomyolysis, especially when used in combination with statins.
Contraindications[edit]
Ciprofibrate is contraindicated in patients with severe hepatic impairment, renal impairment, or gallbladder disease. It should not be used in patients with known hypersensitivity to fibrates.
